Sign in

    Ricki Levitus

    Research Analyst at Guggenheim Securities, LLC

    Ricki Levitus is an Equity Research Associate at Guggenheim Securities, specializing in Life Sciences Tools & Diagnostics. She covers companies including Maravai LifeSciences and Myriad Genetics, contributing to investment research and earnings analysis that informs the firm’s healthcare strategy. Levitus began her career in the sector and advanced to her current role at Guggenheim Partners, where she has participated in high-profile earnings calls and supported senior analysts on notable coverage. Her professional credentials and performance metrics are not publicly listed, but she is recognized for her analytical insight within the healthcare equities space.

    Ricki Levitus's questions to MYRIAD GENETICS (MYGN) leadership

    Ricki Levitus's questions to MYRIAD GENETICS (MYGN) leadership • Q2 2025

    Question

    Ricki Levitus of Guggenheim Partners, on for Subbu Namdi, asked about the performance of the SneakPeek test and its success in funneling patients to Prequel. She also asked for clarification on what is incrementally new in the strategic plan for the Women's Health and Mental Health businesses.

    Answer

    President and CEO Sam Raha acknowledged that the SneakPeek business has been a 'challenge' and is not a primary area of focus at this time. Regarding the strategic update, he explained that for Women's Health and Mental Health, the key change is a 'deliberate' and disciplined approach to resourcing and investment. The goal is to maintain growth at or above market rates in these areas while prioritizing capital and focus on the higher-growth Cancer Care Continuum pillar.

    Ask Fintool Equity Research AI

    Ricki Levitus's questions to CASTLE BIOSCIENCES (CSTL) leadership

    Ricki Levitus's questions to CASTLE BIOSCIENCES (CSTL) leadership • Q3 2024

    Question

    Ricki Levitus, on for Subbu Nambi, asked for an update on the competitive landscape for DecisionDx-Melanoma, particularly in light of new data and partnerships from competitor SkylineDx.

    Answer

    CEO Derek Maetzold stated that Castle has not seen meaningful competitive traction from SkylineDx over the last four years. He critically pointed out that Skyline's recent study data showed a 7.1% sentinel lymph node positivity rate in its low-risk group, which is above the key 5% clinical threshold. He contrasted this with Castle's test, which studies have shown achieves a rate below that important threshold.

    Ask Fintool Equity Research AI